Caroline Seymour


RVd Plus ACST and Lenalidomide Maintenance Promote Efficacy in Newly Diagnosed Multiple Myeloma

June 08, 2022

Patients with multiple myeloma who received initial combination therapy with lenalidomide, bortezomib, and dexamethasone, plus autologous stem cell transplant, followed by lenalidomide maintenance, experienced improved progression-free survival.

Adding Atezolizumab to Chemoradiation Promotes T-Cell Clonal Expansion in Node-Positive Cervical Cancer

March 26, 2022

Whether administered as an immune primer or concurrently with extended field chemoradiation, atezolizumab demonstrated efficacy in triggering T-cell clonal expansions and prolonging progression-free survival in patients with cervical cancer.

NCCN Clinical Practice Guidelines Now Include Duvelisib for Peripheral T-cell Lymphoma

March 17, 2022

Duvelisib, a dual PI3K-δ,γ inhibitor, is now listed as a category 2A designated option for second-line and subsequent treatment of patients with relapsed/refractory peripheral T-cell lymphoma in the National Comprehensive Cancer Network Clinical Practice Guidelines.

Niraparib/Abiraterone Combo Linked to Improved rPFS in Select Patients With mCRPC

February 18, 2022

A frontline regimen of niraparib, abiraterone acetate, and prednisone yielded improved radiographic progression-free survival in patients with homologous recombination repair gene altered–metastatic castration-resistant prostate cancer.